Back to Authors

Growdon, John H.

A5111694111 | I111088046

Mayo Clinic

Boston University

Citations 7

Transethnic genome‐wide scan identifies novel Alzheimer's disease loci

Alzheimer's & Dementia | February 6, 2017 | Volume: 13 | Issue: 7 | Pages: 727-738

10.1016/j.jalz.2016.12.012 | PMID 28183528

Abstract Introduction Genetic loci for Alzheimer's disease (AD) have been identified in whites of European ancestry, but the genetic architecture of AD among other populations is less understood. Methods We conducted a transethnic genome‐wide association study (GWAS) for late‐onset AD in Stage 1 sample including whites of European Ancestry, African‐Americans, Japanese, and Israeli‐Arabs assembled by the Alzheimer's Disease Genetics Consortium. Suggestive results from Stage 1 from novel loci were followed up using summarized results in the International Genomics Alzheimer's Project GWAS dataset. Results Genome‐wide significant (GWS) associations in single‐nucleotide polymorphism (SNP)–based tests ( P < 5 × 10 −8 ) were identified for SNPs in PFDN1/HBEGF , USP6NL/ECHDC3 , and BZRAP1‐AS1 and for the interaction of the (apolipoprotein E) APOE ε4 allele with NFIC SNP. We also obtained GWS evidence ( P < 2.7 × 10 −6 ) for gene‐based association in the total sample with a novel locus, TPBG ( P = 1.8 × 10 −6 ). Discussion Our findings highlight the value of transethnic studies for identifying novel AD susceptibility loci.
Arguing against the proposed definition changes of PD

Movement Disorders | August 5, 2016 | Volume: 31 | Issue: 11 | Pages: 1619-1622

10.1002/mds.26721 | PMID 27492190

ABSTRACT As members of the Lewy Body Dementia Association Scientific Advisory Council, we aim to address some of the issues raised in the article titled “Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease.” In particular, we suggest that the 1‐year rule distinguishing Parkinson's disease dementia from dementia with Lewy bodies is worth maintaining because it serves an important purpose in clinical practice and clinical and basic science research and when helping the lay community understand the complexity of these different clinical phenotypes. Furthermore, we believe that adding an additional diagnostic label, “PD (dementia with Lewy bodies subtype),” will confuse rather than clarify the distinction between dementia with Lewy bodies and PD or PD dementia, and will not improve management or expedite therapeutic development. We present arguments supporting our contentions. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Massachusetts Alzheimer's Disease Research Center: Progress and challenges

Alzheimer's & Dementia | August 19, 2015 | Volume: 11 | Issue: 10 | Pages: 1241-1245

10.1016/j.jalz.2015.06.1887 | PMID 26297855

Rarity of the Alzheimer Disease–ProtectiveAPPA673T Variant in the United States

JAMA Neurology | December 22, 2014 | Volume: 72 | Issue: 2 | Pages: 209

10.1001/jamaneurol.2014.2157 | PMID 25531812

Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease

JAMA Neurology | September 8, 2014 | Volume: 71 | Issue: 11 | Pages: 1394

10.1001/jamaneurol.2014.1491 | PMID 25199842

Genotype patterns atPICALM, CR1, BIN1, CLU, andAPOEgenes are associated with episodic memory

Neurology | April 27, 2012 | Volume: 78 | Issue: 19 | Pages: 1464-1471

10.1212/wnl.0b013e3182553c48 | PMID 22539578

Activity enhances dopaminergic long-duration response in Parkinson disease

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675